Cel Sci (CVM) EBT Margin (2010 - 2017)
Cel Sci (CVM) posted EBT Margin of 27763.06% for Q2 2017, down 507.72% sequentially from 4568.39% in Q2 2016, and down 2319468.0% YoY from N/an in Q2 2016.
Cel Sci (CVM) EBT Margin (2010 - 2017) Analysis & Trends
Cel Sci has reported EBT Margin for 4 years, with the latest figure at 27763.06% in Q2 2017.
- Quarterly EBT Margin fell 2319468.0% year-over-year to 27763.06% in Q2 2017, while the trailing twelve-month figure through Jun 2017 was 6718.48% (down 185788.0% YoY) and the FY2011 annual result came in at 3849.47%, up 1582621.0% from the prior year.
- EBT Margin declined to 27763.06% in Q2 2017 per CVM's latest filing, from 4568.39% in the prior quarter.
- Over five years, EBT Margin peaked at 4568.39% in Q2 2016 and troughed at 27763.06% in Q2 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.61 Bn | 131.75 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 65.28 Bn | 60.09 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 59.14 Bn | 54.00 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 42.13 Bn | 37.03 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 31.83 Bn | 28.52 Bn | 992.69 Mn | 13.77% |
| 7 | BioNTech SE | 28.07 Bn | 9.68 Bn | 668.28 Mn | -25.06% |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn | -2.67% |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 12.09% |
| 10 | Cel Sci | 2.21 Mn | -4.33 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2017 | -27,763.06% |
| Jun 30, 2016 | -4,568.39% |
| Sep 30, 2011 | -2,248.85% |
| Jun 30, 2011 | -4,023.43% |
| Sep 30, 2010 | -3,624.58% |